Company Overview and News

 
Steel still in demand

2018-10-05 thestar.com.my
The steel industry, being one of the main arteries of the industrial age continues to be in demand till this very day given the metal’s widespread usage in various other industries.
5665 7020 6556 5098

 
Masteel 2Q net profit down 25% on forex loss

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Malaysia Steel Works (KL) Bhd (Masteel) posted a 24.6% drop in net profit to RM7.98 million in the second quarter ended June 30, 2018 (2QFY18) from RM10.59 million a year ago, mainly due to a foreign exchange (forex) loss compared with a forex gain in 2QFY17.
5098

1
The Week Ahead: Focus on oil price and full Cabinet line-up

2018-06-18 theedgemarkets
The possible announcement of the full Cabinet line-up could be among the highlights this week, even as businesses continue to cash in on the World Cup 2018 fever and the zero-rated Goods and Services Tax (GST) “tax holiday”. There was no Cabinet meeting last Wednesday (June 13) with Prime Minister Tun Dr Mahathir Mohamad just returning from a work trip in Japan (June 11 and 12) and Hari Raya Puasa festivities on June 15 and 16.
8591 5139 9571 5797 1996 0900 5263 5098 0065 5156

5
Trading ideas: MISC, CCM, Masteel, Power Root, Sime Darby

2018-05-28 thestar.com.my
KUALA LUMPUR: JF Apex Research expects MISC Bhd , Chemical Co of Malaysia Bhd (CCM), Malaysia Steel Works (KL) Bhd (Masteel), Power Root Bhd and Sime Darby Bhd to be among the stocks to watch on Monday.
SMEBF 4197 5098 7237

7
Steel stocks on a roll

2018-04-10 thestar.com.my
KUALA LUMPUR: Shares of steel companies on Bursa Malaysia traded higher in early trade Tuesday as metal prices became firmer.
5665 6556 8869 5098 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...